2025-05-30 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. The report is structured as requested, with key numbers upfront, followed by analysis.

**Report on Johnson & Johnson (JNJ)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 20.27%
*   **VOO Cumulative Return:** 82.09%
*   **Absolute Divergence:** -61.8%
*   **Relative Divergence:** 15.5% (meaning the current divergence is in the lower 15.5% percentile of its historical range).

**Analysis of Divergence:**

JNJ has significantly underperformed the S&P 500 (VOO) over the period examined. The relative divergence suggests this underperformance is near the lower end of its historical range compared to the S&P 500. This could indicate a potential opportunity for JNJ to catch up, or it could be a sign of fundamental issues driving the underperformance.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha    | Beta | Cap(B) |
|------------|---------|-------|----------|------|--------|
| 2015-2017  | 28.0%  | 56.4% | -1.0%    | 0.0  | 272.6  |
| 2016-2018  | 10.0%  | 10.8% | -7.0%    | 0.0  | 258.6  |
| 2017-2019  | 20.0%  | 10.8% | -9.0%    | 0.7  | 300.5  |
| 2018-2020  | 14.0%  | 59.8% | -12.0%   | 0.5  | 333.0  |
| 2019-2021  | 28.0%  | 59.8% | -26.0%   | 0.3  | 371.1  |
| 2020-2022  | 4.0%   | 61.2% | -2.0%    | 0.3  | 393.3  |
| 2021-2023  | -19.0% | 61.2% | -35.0%   | 0.4  | 359.6  |
| 2022-2024  | -30.0% | 61.2% | -47.0%   | 0.3  | 342.3  |
| 2023-2025  | -6.0%  | 69.6% | -36.0%   | 0.2  | 369.5  |

**Analysis of Alpha/Beta Table:**

*   **Alpha:**  The consistent negative Alpha indicates JNJ has underperformed its benchmark (likely the S&P 500) on a risk-adjusted basis over most periods.  The magnitude of the negative alpha has increased significantly in recent years.
*   **Beta:**  The Beta values are generally low (around 0.3-0.7), indicating that JNJ's price is less volatile than the overall market.
*   **CAGR:** Recent CAGR are negative, suggesting that JNJ has had a poor performance over the past few years.
*   **MDD:** The Maximum Drawdown (MDD) is relatively high, which means that the stock price of JNJ has experienced large drops in the past.
*   **Cap(B):** The market capitalization has generally increased.

**2. Recent Price Action**

*   **Current Price:** 153.58
*   **Last Market Data:** Price: 153.58, Previous Close: 152.43, Change: 0.75
*   **5-day Moving Average:** 152.44
*   **20-day Moving Average:** 151.96
*   **60-day Moving Average:** 155.68

**Analysis of Price Action:**

The price is currently above both the 5-day and 20-day moving averages, suggesting a short-term upward trend. However, it is below the 60-day moving average, which could indicate that the longer-term trend is still downward or sideways.  The recent positive change of 0.75 suggests upward momentum.

**3. Market Risk Indicators and Expectations**

*   **Market Risk Indicator (MRI):** 0.37 (Low Risk)
*   **RSI:** 48.23
*   **PPO:** 0.29
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** -0.2 (negative, indicating recent underperformance)
*   **Expected Return:** -166.4% (vs. S&P 500, long-term)

**Analysis of Indicators:**

*   **MRI:** A low MRI suggests relatively low market risk at the moment.
*   **RSI:** An RSI of 48.23 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** The PPO is around 0, and this can be interpreted as a neutral signal.
*   **Hybrid Signal:** The hybrid signal recommends buying 80% of cash with caution.
*   **Recent Divergence Change:** The negative change in relative divergence confirms the recent underperformance compared to the S&P 500.
*   **Expected Return:** A negative expected return of -166.4% (relative to the S&P 500) is highly concerning. It suggests the model predicts significant underperformance in the long term.

**4. Recent News & Significant Events**

*   **[2025-05-30]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-26]:** Analysts discussing performance and outlook.
*   **[2025-05-28]:** Notable stock volatility.
*   **[2025-05-29]:** Market experts highlight both risks and opportunities.

**Analysis of News:**

The news snippets suggest recent volatility and potential significant events affecting JNJ. These events likely contribute to the uncertain outlook reflected in the technical indicators and relative performance.  Investors should monitor news and company announcements closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

**Analysis of Earnings:**

*   **EPS:** The EPS figures are fluctuating.
*   **Revenue:** The revenue figures are relatively stable, hovering around $22 billion per quarter.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue      | Profit Margin |
|--------------|--------------|---------------|
| 2025-03-31   | $21.89B      | 66.40%        |
| 2024-12-31   | $22.52B      | 68.35%        |
| 2024-09-30   | $22.47B      | 69.01%        |
| 2024-06-30   | $22.45B      | 69.40%        |
| 2024-03-31   | $21.38B      | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity        | ROE     |
|--------------|---------------|---------|
| 2025-03-31   | $78.11B      | 14.08%   |
| 2024-12-31   | $71.49B      | 4.80%    |
| 2024-09-30   | $70.16B      | 3.84%    |
| 2024-06-30   | $71.54B      | 6.55%    |
| 2024-03-31   | $70.02B      | 4.65%    |

**Analysis of Financial Information:**

*   **Revenue:** Revenue has been relatively stable.
*   **Profit Margin:** Profit margins have slightly decreased over the past year.
*   **Equity:** Equity has increased over the past year.
*   **ROE:** ROE is fluctuating.

**7. Overall Analysis and Summary**

Johnson & Johnson (JNJ) is currently underperforming the S&P 500.  The negative Alpha and the large negative expected return are significant concerns. Recent news suggests potential business developments and volatility. While revenue has been relatively stable, profit margins have slightly decreased.  The technical indicators provide mixed signals, but the overall picture suggests caution.
